Compare DSGN & AVNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGN | AVNS |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.9M | 521.7M |
| IPO Year | 2021 | 2014 |
| Metric | DSGN | AVNS |
|---|---|---|
| Price | $10.28 | $13.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $15.25 | N/A |
| AVG Volume (30 Days) | 242.4K | ★ 568.3K |
| Earning Date | 03-09-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $701,200,000.00 |
| Revenue This Year | N/A | $3.28 |
| Revenue Next Year | N/A | $4.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $2.62 | $9.30 |
| 52 Week High | $11.23 | $15.68 |
| Indicator | DSGN | AVNS |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 46.87 |
| Support Level | $9.64 | $13.45 |
| Resistance Level | $11.14 | $15.68 |
| Average True Range (ATR) | 0.59 | 0.51 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 42.21 | 47.65 |
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.